Sign in

    Sheri L. Dodd

    Chief Executive Officer (CEO) at Tactile Systems Technology Inc
    Board
    Since July 1, 2024
    Age
    59 years
    Education
    Holds a Bachelor of Science degree from the College of Idaho and a Master of Science in Health Planning and Financing from the London School of Economics and London School of Hygiene and Tropical Medicine.
    Tenure
    Joined the Board of Directors in January 2021 and began serving as Chief Executive Officer on July 1, 2024.

    Also at Tactile Systems Technology Inc

    EMB
    Elaine M. Birkemeyer
    Chief Financial Officer (CFO)
    KTB
    Kristie T. Burns
    SVP, Marketing & Clinical Affairs

    About

    Sheri L. Dodd has built an impressive career spanning nearly 30 years in the healthcare industry and now leads as the Chief Executive Officer at TCMD, where her extensive experience in global pharmaceutical, medical device, and digital health sectors fuels her commitment to advancing patient care.

    Having held senior roles at esteemed organizations including Medtronic plc, where she managed critical commercial and clinical functions, and Johnson & Johnson, where her work in health economics and reimbursement strategies made a significant impact, she also contributed to global health initiatives during her tenure with the World Health Organization.

    At TCMD, her leadership is characterized by a strategic focus on innovation, market expansion, and operational excellence. The transition to the CEO role underscores her dedication to driving sustainable growth and improving access to care, leveraging her deep expertise and robust industry background to steer the company through a dynamic healthcare landscape.

    $TCMD Performance Under Sheri L. Dodd

    Past Roles

    OrganizationRoleDate RangeDetails
    Tactile Systems Technology, Inc. Board of Directors Jan 2021 – Jul 2024 Served on the Board prior to becoming CEO
    Medtronic plc President of Medtronic Canada Mar 2010 – Jun 2024 Responsible for all commercial activities in Canada
    Medtronic plc Vice President and General Manager of Medtronic Care Management Services Mar 2010 – Jun 2024 Focused on caring for complex patients in the home
    Medtronic plc Vice President and General Manager of Non-intensive Diabetes Therapies Mar 2010 – Jun 2024 N/A
    Medtronic plc Vice President for Global Health Economics, Reimbursement & Policy, and Global Clinical Research Mar 2010 – Jun 2024 Oversaw initiatives across the cardiovascular portfolio
    Johnson & Johnson Vice President of Health Economics and Reimbursement for Ethicon, Inc. Nov 1997 – Mar 2010 Held various roles in the pharmaceutical and medical devices divisions
    Orthopedic Surgeons, plc Outcomes Researcher Jan 1995 – Nov 1997 N/A
    World Health Organization (WHO) Project Coordinator May 1988 – Sep 1993 N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Annual Base Salary$650,000 AnnuallyFixed annual pay
    Restricted Stock Units$875,000 Vests in thirds over the first three anniversariesGranted under the 2016 Equity Incentive Plan

    Performance Compensation

    Data from  FY 2024

    Annual Cash Bonus

    Metric [Description]Value/DetailAdditional Details
    Target Amount90% of base salary (approx. $585,000) Based on an annual base salary of $650,000
    Performance MetricsN/A Specific performance metrics not provided
    Evaluation Period2024 In line with the management incentive plan
    Payment ScheduleAnnualPaid upon meeting undisclosed performance criteria

    Performance Stock Units (PSUs)

    Metric [Description]Value/DetailAdditional Details
    Target Award Value$850,000 Total target value of PSUs awarded in 2024
    Performance MetricsRevenue Change (2024), Adjusted EBITDA Margin (2024), Adjusted EBITDA Change (2025) For 2026, performance goals will be established
    Threshold & Cap Range25% to 175% Earned based on achievement of performance goals
    Vesting Schedule3 years PSUs vest over three years
    Grant DateSecond business day following Q2 earnings release Determined based on the earnings announcement schedule
    Grant Date Fair Value$850,000 Reflects the award's fair value at grant date
    Grant Date Stock PriceN/A Specific stock price on the grant date not provided
    SettlementShares of common stock PSUs will be settled in shares once earned and vested
    Unrecognized Expense$1.5 million Total unrecognized pre-tax compensation expense as of June 30, 2024; recognized over a weighted average of 2.2 years